PINX:BSRC BioSolar Inc Quarterly Report 10-Q Filing - 6/30/2012

Effective Date 6/30/2012

PINX:BSRC (BioSolar Inc): Fair Value Estimate
Premium
PINX:BSRC (BioSolar Inc): Consider Buying
Premium
PINX:BSRC (BioSolar Inc): Consider Selling
Premium
PINX:BSRC (BioSolar Inc): Fair Value Uncertainty
Premium
PINX:BSRC (BioSolar Inc): Economic Moat
Premium
PINX:BSRC (BioSolar Inc): Stewardship
Premium
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012
 
¨ TRANSITION REPORT UNDER SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________

COMMISSION FILE NUMBER: 333-138910

BIOSOLAR, INC.
(Name of registrant in its charter)

Nevada
 
20-4754291
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
27936 Lost Canyon Road, Suite 202 , Santa Clarita, CA 91387
(Address of principal executive offices) (Zip Code)

Issuer’s telephone Number: (661) 251-0001

WITH COPIES TO:

Gregory Sichenzia, Esq.
Marcelle S. Balcombe, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 nd Flr.
New York, New York 10006
(212) 930-9700

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  o No  x
 
The number of shares of registrant’s common stock outstanding, as of July 31, 2012 was 6,284,413.




 


 
 
INDEX
 




 
 
PART I   – FINANCIAL INFORMATION  
 

BIOSOLAR, INC.
(A Development Stage Company)


   
June 30, 2012
   
December 31, 2011
 
   
(Unaudited)
       
ASSETS
           
             
CURRENT ASSETS
           
   Cash
  $ 74,162     $ 52,422  
   Prepaid expenses
    20,283       30,797  
                 
                        TOTAL CURRENT ASSETS
    94,445       83,219  
                 
PROPERTY AND EQUIPMENT
               
   Machinery and equipment
    78,864       76,281  
   Computer
    2,928       2,928  
      81,792       79,209  
   Less accumulated depreciation
    (30,692 )     (26,698 )
                 
                       NET PROPERTY AND EQUIPMENT
    51,100       52,511  
                 
OTHER ASSETS
               
   Patents, net of amortization of $40
    142,008       140,927  
   Deposit
    770       770  
                 
                       TOTAL OTHER ASSETS
    142,778       141,697  
                 
                       TOTAL ASSETS
  $ 288,323     $ 277,427  
                 
                 
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
               
                 
CURRENT LIABILITIES
               
   Accounts payable
  $ 7,915     $ 4,377  
   Accrued expense
    104,517       13,145  
                 
                       TOTAL CURRENT LIABILITIES
    112,432       17,522  
                 
SHAREHOLDER'S EQUITY
               
   Common stock, $0.0001 par value;
               
   500,000,000 authorized common shares
               
   6,239,413 and 5,536,164 shares issued and outstanding, respectively
    623       554  
   Additional paid in capital
    5,450,670       5,040,120  
   Deficit accumulated during the development stage
    (5,275,402 )     (4,780,769 )
                 
                      TOTAL SHAREHOLDERS' EQUITY
    175,891       259,905  
                 
                      TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
  $ 288,323     $ 277,427  
                 

The accompanying notes are an integral part of these financial statements
 
 

 
 
BIOSOLAR, INC.
(A Development Stage Company)
(Unaudited)


                           
From Inception
 
                           
April 24, 2006
 
   
Three Months Ended
   
Six Months Ended
   
through
 
   
June 30, 2012
   
June 30, 2011
   
June 30, 2012
   
June 30, 2011
   
June 30, 2012
 
                               
REVENUE
  $ -     $ -     $ -     $ -     $ -  
                                         
OPERATING EXPENSES
                                       
General and administrative expenses
    176,716       316,240       452,728       512,830       4,557,222  
Research and development
    3,741       8,670       37,735       21,857       773,565  
Depreciation and amortization
    2,008       2,034       3,994       4,030       30,732  
                                         
TOTAL OPERATING EXPENSES
    182,465       326,944       494,457       538,717       5,361,519  
                                         
LOSS FROM OPERATIONS BEFORE  OTHER INCOME/(EXPENSES)
    (182,465 )     (326,944 )     (494,457 )     (538,717 )     (5,361,519 )
                                         
TOTAL OTHER INCOME/(EXPENSES)
                                       
    Interest income
    5       58       14       58       87,249  
    Penalties
    -       -       -       -       (180 )
    Interest expense
    -       (229 )     (190 )     (458 )     (952 )
                                         
TOTAL OTHER INCOME/(EXPENSES)
    5       (171 )     (176 )     (400 )     86,117  
                                         
                                         
         NET LOSS
  $ (182,460 )   $ (327,115 )   $ (494,633 )   $ (539,117 )   $ (5,275,402 )
                                         
                                         
BASIC AND DILUTED LOSS PER SHARE
  $ (0.03 )   $ (0.06 )   $ (0.08 )   $ (0.10 )        
                                         
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
                                 
      BASIC AND DILUTED
    6,110,971       5,364,707       5,978,707       5,301,367          
                                         


The accompanying notes are an integral part of these financial statements







BIOSOLAR, INC.
(A Development Stage Company)


                               
                               
                     
Deficit
       
                        Accumulated      
               
Additional
   
during the
       
   
Common stock
   
Paid-in
      Development      
   
Shares
   
Amount
   
Capital
   
Stage
   
Total
 
Balance at December 31, 2011
    5,536,164     $ 554     $ 5,040,120     $ (4,780,769 )   $ 259,905  
                                         
Issuance of common shares for cash
                                       
(prices ranging between $0.55 and $0.70 per share) (unaudited)
    369,412       36       229,764       -       229,800  
                                         
Issuance of commn stock for warrants through a cashless exercise (unaudted)
    332,602       33       (33 )     -       -  
                                         
Issuance of common stock for subscription receivable
                                       
(price of $0.66 per share) (unaudited)
    18,812       2       12,414       -       12,416  
                                         
Cancellation of subscription receivable (unaudited)
    (17,577 )     (2 )     (11,599 )     -       (11,601 )
                                         
Stock compensation cost (unaudited)
    -       -       180,004       -       180,004  
                                         
Net loss for the six months ended June 30, 2012 (unaudited)
    -       -       -       (494,633 )     (494,633 )
                                         
Balance at June 30, 2012 (unaudited)
    6,239,413     $ 623     $ 5,450,670     $ (5,275,402 )   $ 175,891  
                                         

The accompanying notes are an integral part of these financial statements








BIOSOLAR, INC.
(A Development Stage Company)
(Unaudited)


                   
               
From Inception
 
               
April 24, 2006
 
   
Six Months Ended
   
through
 
   
June 30, 2012
   
June 30, 2011
   
June 30, 2012
 
CASH FLOWS FROM OPERATING ACTIVITIES:
                 
    Net loss
  $ (494,633 )   $ (539,117 )   $ (5,275,402 )
    Adjustment to reconcile net loss to net cash
                       
      used in operating activities
                       
    Depreciation expense
    3,994       4,030       30,732  
    Issuance of stock for services
    -       -       325,262  
    Stock compensation cost
    180,004       158,880       614,249  
  Changes in Assets and Liabilities
                       
    (Increase) Decrease in:
                       
    Inventory
    -       -       -  
    Prepaid expenses
    10,514       (14,137 )     (20,283 )
    Deposits
    -       -       (770 )
    Increase (Decrease) in:
                       
    Accounts payable
    3,538       5,042       7,915  
    Accrued expenses
    91,372       -       104,517  
                         
NET CASH USED IN OPERATING ACTIVITIES
    (205,211 )     (385,302 )     (4,213,780 )
                         
CASH FLOWS FROM INVESTING ACTIVITIES:
                       
    Purchase of equipment
    (2,583 )     -       (81,792 )
    Patent expenditures
    (1,081 )     (16,754 )     (142,048 )
                         
NET CASH USED IN INVESTING ACTIVITIES
    (3,664 )     (16,754 )     (223,840 )
                         
CASH FLOWS FROM FINANCING ACTIVITIES:
                       
    Proceeds from common stock subscription payable
    -       -       203,000  
Proceeds from issuance of common stock
    230,615       441,000       4,308,782  
                         
NET CASH PROVIDED IN FINANCING ACTIVITIES
    230,615       441,000       4,511,782  
                         
NET INCREASE IN CASH
    21,740       38,944       74,162  
                         
CASH, BEGINNING OF PERIOD
    52,422       44,318       -  
                         
CASH, END OF PERIOD
  $ 74,162     $ 83,262     $ 74,162  
                         
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
                 
   Interest paid
  $ 190     $ 229     $ -  
   Taxes paid
  $ -     $ -     $ -  
                         
SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS
                 
   Common stock issued for prepaid services
  $ -     $ -     $ 5,867  
                         
During the six months ended June 30, 2012, the Company issued 332,602 shares of common stock for warrants through a cashless exercise.
 
Also, the Company issued 18,812 shares of common stock for a subscription receivable, of which 17,577 was overstated and unsubscribed.
 
                         

The accompanying notes are an integral part of these financial statements






BIOSOLAR, INC.
(A Development Stage Company)
June 30, 2012
 
 
 
1. 
Basis of Presentation
The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included.  Operating results for the six months ended June 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.  For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2011.

Going Concern
The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business.  The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern.  To date the Company has not generated any revenues, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.  The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion.  The Company has obtained funds from its shareholders since its inception. It is Management's plan to generate additional working capital from investors, and then continue to pursue its business plan and purposes.

2. 
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Biosolar, Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Development Stage Activities and Operations
The Company is in its initial stages of formation and has insignificant revenues. A development stage activity is one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.

Revenue Recognition
The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has had no revenues and is in the development stage.

Cash and Cash Equivalent
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Investments
Certificate of Deposits with banking institutions are short-term investments with initial maturities of more than 90 days. The carrying amount of these investments is a reasonable estimate of fair value due to their short-term nature.

Loss per Share Calculations
Loss per Share calculates basic earnings per share and diluted earnings per share. Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the six months ended June 30, 2012 as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.
 
 

BIOSOLAR, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS-UNAUDITED
June 30, 2012
 

2. 
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Issued Accounting Pronouncements

 
Management reviewed accounting pronouncements issued during the six months ended June 30, 2012, and no pronouncements were adopted during the period which would have a material effect on the accompanying financial statements.

3.
CAPITAL STOCK

During the six months ended June 30, 2012, the Company issued 37,880 shares of common stock at a price of   $0.66 per share for cash of $25,000; issued 18,812 shares of common stock for a subscription receivable in the amount of $12,416 during the period ended March 31,2012, of which $11,601 was refunded to the investor and  17,577 shares of common stock were cancelled during the period ended June 30, 2012. The remaining 1,235 shares of common stock were purchased at a price of $0.66 per share for cash of $815. In addition the Company issued 149,714 shares of common stock at a price of $0.70 per share for cash of $104,799; Also, through a cashless exercise of a warrant, the Company issued 332,602 shares of common stock.
 
During the six months ended June 30, 2011, the Company issued 28,986 shares of common stock at a price of $1.725 per share for cash of $50,000, with warrants attached to purchase 57,971 shares of common stock; issued 164,444 shares of common stock at a price of $2.25 per share for cash of $370,000, with warrants attached to purchase 88,889 shares of common stock; issued 10,000 shares of common stock at a price of $2.10 per share for cash of $21,000.
 
4. 
STOCK OPTIONS AND WARRANTS

On March 24, 2011, the Board of Directors of the Company granted non-qualified stock options to purchase 236,667 shares of common stock to its employees, directors and consultants. Notwithstanding any other provisions of the Option agreement, each Option expires on the date specified in the Option agreement, which date shall not be later than the fifth (5th) anniversary from the grant date of the options. The stock options vest at various times, and are exercisable at an exercise price of $4.05 per share, the market value of the Company’s common stock on the date of grant.
 
Risk free interest rate
    2.14 %
Stock volatility factor
    1 %
Weighted average expected option life
 
5 years
 
Expected dividend yield
 
None
 

A summary of the Company’s stock option activity and related information follows:
 
   
6/30/2012
 
         
Weighted
 
   
Number
   
average
 
   
of
   
exercise
 
   
Options
   
price
 
Outstanding, beginning of period
    236,667     $ 4.05  
Granted
    -       -  
Exercised
    -       -  
Expired
    -       -  
Outstanding, end of period
    236,667     $ 4.05  
Exercisable at the end of period
    195,186     $ 3.15  
Weighted average fair value of
               
options granted during the period
    $ -  
                 
 
 
 
 

BIOSOLAR, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS-UNAUDITED
June 30, 2012
 
4. 
STOCK OPTIONS AND WARRANTS (Continued)

The weighted average remaining contractual life of options outstanding as of June 30, 2012 was as follows:
 
     
Weighted
     
Average
 
Stock
Stock
Remaining
Exercisable
Options
Options
Contractual
Prices  Outstanding 
 Exercisable
 Life (years)
$4.050 236,667 195,186 3.73

The stock-based compensation expense recognized in the statement of operations during the six months ended June 30, 2012, related to the granting of these options is $180,004.

Warrants
During the six months ended June 30, 2012, the Company granted warrants to purchase 239,394 shares of common stock exercisable at a price between $0.55 and $0.70 per share within five years from the date of grant. The warrants were attached to 119,698 shares of common stock purchased through a private placement. Through a cashless exercise, 664,036 warrants were exercised to purchase 332,602 shares of common stock. As of June 30, 2012, 95,000 warrants were outstanding.
 
5.
SUBSEQUENT EVENT

 
Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and reported the following:

 
On July 16, 2012, the Company received funds in the amount of $24,750, to purchase 45,000 shares of common stock at a price per share of $0.55.



 
 
I TEM 2:  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Special Note on Forward-Looking Statements.

Certain statements in “Management’s Discussion and Analysis or Plan of Operation” below, and elsewhere in this quarterly report, are not related to historical results, and are forward-looking statements. Forward-looking statements present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements frequently are accompanied by such words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or the negative of such terms or other words and terms of similar meaning. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or timeliness of such results. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this report. Subsequent written and oral forward looking statements attributable to us or to persons acting in our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in our annual report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2012, and in other reports filed by us with the SEC.

You should read the following description of our financial condition and results of operations in conjunction with the financial statements and accompanying notes included in this report.
 
Overview
 
We are developing an innovative technology to produce bio-based materials from renewable plant sources that will reduce the cost per watt of Photovoltaic solar modules. Most of the solar industry is focused on photovoltaic efficiency to reduce cost, but we are introducing a new dimension of cost reduction by replacing petroleum-based plastic solar module components with durable bio-based components. The process for producing electricity from sunlight is known as Photovoltaics. Photovoltaic ("PV") is the science of capturing and converting sun light into electricity.

We are focusing our research and product development efforts on producing bio-based components that meet the thermal and durability requirements of current PV solar module manufacturing processes for conventional crystalline cell designs as well as thin film PV devices in an effort to capitalize on what we perceive as cost advantages to current petroleum based PV solar module components.

We are focusing our research and product development efforts on bio-based backsheets, substrates,  superstrates, module, and panel components.
 
We were incorporated in the State of Nevada on April 24, 2006, as BioSolar Labs, Inc. Our name was changed to BioSolar, Inc. on June 8, 2006. Our principal executive offices are located at 27936 Lost Canyon Road, Suite 202, Santa Clarita, California 91387, and our telephone number is (661) 251-0001. Our fiscal year end is December 31.

Application of Critical Accounting Policies
 
Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Black Scholes option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.


 
Use of Estimates

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to recording net revenue, collectibility of accounts receivable, useful lives and impairment of tangible and intangible assets, accruals, income taxes, inventory realization, stock-based compensation expense and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

Fair Value of Financial Instruments

Our cash, cash equivalents, investments, inventory, prepaid expenses, and accounts payable are stated at cost which approximates fair value due to the short-term nature of these instruments.
 
Recently Issued Accounting Pronouncements

            Management reviewed accounting pronouncements issued during the three months ended June 30, 2012 and no pronouncements were adopted during the period that would have a material impact on our financial statments.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2012 COMPARED TO THE THREE MONTHS ENDED JUNE 30, 2011

OPERATING EXPENSES

General and Administrative Expenses

General and administrative (“G&A”) expenses decreased by $(139,524) to $176,716 for the three months ended June 30, 2012, compared to $316,240 for the prior period June 30, 2011. This decrease in G&A expenses was the result of a decrease in non-cash stock compensation expense of $(91,273) and a decrease in public relations expense of $(46,028) as well as an overall decrease in other expenses of $(2,223).
 
Research and Development

Research and Development (“R&D”) expenses decreased by $(4,929) to $3,741 for the three months ended June 30, 2012, compared to $8,670 for the prior period June 30, 2011. This overall decrease in R&D expenses was the result of a decrease in consulting fees.

Net Loss

Our Net Loss decreased by $(144,655) to $(182,460) for the three months ended June 30, 2012, compared to $(327,115) for the prior period June 30, 2011. The decrease in Net Loss was due to the overall decrease in non-cash stock compensation expense, and the overall decrease in operating expenses.  Currently, the Company is in its development stage and has no revenues.

RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2012 COMPARED TO THE SIX MONTHS ENDED JUNE 30, 2011

OPERATING EXPENSES

General and Administrative Expenses

General and administrative (“G&A”) expenses decreased by $(60,102) to $452,728 for the six months ended June 30, 2012, compared to $512,830 for the prior period June 30, 2011. This decrease in G&A expenses was the result of an increase in non-cash stock compensation expense of $21,124 and a decrease in public relations of $(78,321), and an overall decrease in G&A expenses of $(2,905).

 
 



Research and Development

Research and Development (“R&D”) expenses increased by $15,878 to $37,735 for the six months ended June 30, 2012, compared to $21,857 for the prior period June 30, 2011. This overall increase in R&D expenses was the result of an increase in materials and supplies for samples and testing the product.

Net Loss

Our Net Loss decreased by $(44,484) to $(494,633) for the six months ended June 30, 2012, compared to $(539,117) for the prior period June 30, 2011. The increase in Net Loss was due to an increase in non-cash stock compensation expense of $21,124 and an overall decrease in operating expenses of $(65,608).  Currently the Company is in its development stage and has no revenues.
 
LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2012, we had $(17,987) of working capital deficit as compared to $65,697 for the year ended December 31, 2011. This decrease of $(83,684) was due primarily to an overall increase in accounts payable and accrued expenses.
 
During the six months ended June 30, 2012, the Company used $(205,211) of cash for operating activities, as compared to $(385,302) for the prior period June 30, 2011. The decrease of $(180,091) in the use of cash for operating activities was primarily due to an overall decrease in net loss, prepaid expenses, and accounts payable, with an increase in accrued expenses.

Cash used in investing activities for the six months ended June 30, 2012 was $(3,664), as compared to $(16,754) for the prior period ended June 30, 2011. The decrease of $(13,090) in investing activities was due primarily to a decrease in patent expenditures in the current period compared to the prior period.
 
Cash provided from financing activities was $230,615 for the six months ended June 30, 2012, as compared to $441,000 for the prior period ended June 30, 2011. Our capital needs have primarily been met from the proceeds of private placements, as we are currently in the development stage and have no revenues.
 
Our financial statements as of June 30, 2012 have been prepared under the assumption that we will continue as a going concern from inception (April 24, 2006) through June 30, 2012. Our independent registered public accounting firm has issued their report dated March 29, 2012 that included an explanatory paragraph expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available. Our ability to continue as a going concern ultimately is dependent on our ability to generate a profit which is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
PLAN OF OPERATION AND FINANCING NEEDS
 
We are engaged in the development of an innovative technology to produce bio-based materials from renewable plant sources that will reduce the cost per watt of Photovoltaic solar modules.

Our plan of operation within the next twelve months is to commercialize our bio-based backsheet component (BioBacksheetTM) to replace the petroleum based backsheet in crystalline photovoltaic modules. This includes high volume production in response to purchase orders from major PV panel manufacturers. In addition, we intend to further enhance test programs to determine the physical properties and characteristics that will be most suitable for the further development of biobased solar module components, and build solar modules, as we attempt to validate the commercial viability of our future products. We believe that our current cash and investment balances will be sufficient to support development activity and general and administrative expenses for the next three months. Management estimates that we will require additional cash resources during 2012, based upon our current operating plan and condition. We will be exploring additional financing alternatives, including equity and/or debt financing. There is no assurance that capital in any form would be available to us, and if available, on terms and conditions that are acceptable. If we are unable to obtain sufficient funds during the next six months, we may be forced to reduce the size of our organization, which could have a material adverse impact on, or cause us to curtail and/or cease the development of our products.
 
Off-Balance Sheet Arrangements
 
We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures.

  
n/a
 
ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.






 



PART II - OTHER INFORMATION
  

We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.
 
 
ITEM 1A. RISK FACTORS
 
There are no material changes from the risk factors previously disclosed in the Registrant’s Form 10-K filed on March 29, 2012
 
 
During the three months ended June 30, 2012,  the Company issued 181,818 shares of common stock at a price of $0.55 per share for cash of $100,000. The Company issued 18,812 shares of common stock for a subscription receivable in the amount of $12,416 during the period ended March 31, 2012, of which $11,601 was refunded to the investor, and 17,577 shares of common stock were cancelled during the period ended June 30, 2012. The remaining 1,235 shares of common stock were purchased at a price of $0.66 per share for cash of $815.
 
Also, through a cashless exercise,  164,634 purchase warrants were exercised for 82,401 shares of common stock during the three months ended June 30, 2012.
 
 
None
 
ITEM 4. MINE SAFETY DISCLOSURES
 
Not applicable.


None
 



 
 
 

EX-101.INS
 
XBRL Instance Document
     
EX-101.SCH
 
XBRL Taxonomy Extension Schema Document
     
EX-101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase
     
EX-101.DEF
 
XBRL Taxonomy Extension Definition Linkbase
     
EX-101.LAB
 
XBRL Taxonomy Extension Labels Linkbase
     
EX-101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase
 
 
 
 

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 3, 2012.
 
 
 
BIOSOLAR
 
       
 
By:
/s/ David Lee    
   
Chief Executive Officer (Principal Executive
 
   
Officer ) and Acting Chief Financial Officer
 
   
(Principal Financial Officer and Principal Accounting Officer)
 

 
 
 
 
 
 
 
 

 


16

PINX:BSRC BioSolar Inc Quarterly Report 10-Q Filling

BioSolar Inc PINX:BSRC Stock - Get Quarterly Report SEC Filing of BioSolar Inc PINX:BSRC stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

PINX:BSRC BioSolar Inc Quarterly Report 10-Q Filing - 6/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: PINX:BSRC BioSolar Inc Quarterly Report 10-Q Filing - 3/31/2012  |  Next: PINX:BSYN Biosynergy Inc Annual Report 10-K Filing - 4/30/2012